RT Generic
T1 A genetic view of laryngeal cancer heterogeneity.
A1 de-Miguel-Luken, Maria Jose
A1 Chaves-Conde, Manuel
A1 Carnero, Amancio
K1 Molecular biology
K1 biomarker
K1 laryngeal cancer treatment
K1 larynx preservation
K1 larynx/laryngeal cancer
AB During the recent decades significant improvements in the understanding of laryngeal molecular biology allowed a better characterization of the tumor. However, despite increased molecular knowledge and clinical efforts, survival of patients with laryngeal cancer remains the same as 30 years ago. Although this result may not make major conclusions as preservation approaches were not broadly used until the time of database collection, it seems to be clear that there is still window for improvement. Although the cornerstone for laryngeal cancer eradication is to implement smoking cessation programs, survival progresses will be hopefully seen in the future. Introducing molecular biomarkers as predictive factors to determine which patients will benefit of preservation treatments may become one of the next steps to improve survival. Furthermore, the development of new therapeutic modalities joint to biomarkers to selectively apply such new therapy in these patients may help to define new modalities with improved survival. New inhibitors against Notch pathway, EGFR, VRK1 or DNA damage repair may become gold standard if we are able to identify patients that may benefit from them, either on survival or functional larynx preservation. It is the moment for an inflexion point on the way laryngeal cancer is clinically managed.
PB Taylor & Francis Inc.
YR 2016
FD 2016-04-25
LK http://hdl.handle.net/10668/9892
UL http://hdl.handle.net/10668/9892
LA en
NO de Miguel-Luken MJ, Chaves-Conde M, Carnero A. A genetic view of laryngeal cancer heterogeneity. Cell Cycle. 2016 May 2;15(9):1202-12
DS RISalud
RD Apr 17, 2025